DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

DISPOSITION IN NORMAL VOLUNTEERS OF SODIUM AZODISALICYLATE, A POTENTIAL THERAPEUTIC AGENT IN INFLAMMATORY BOWEL-DISEASE

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Willoughby, C, Aronson, J, Agback, H, Bodin, N, Andersson, E, Truelove, S
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	1981

Παρόμοια τεκμήρια

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
ανά: Willoughby, C, κ.ά.
Έκδοση: (1982)

Disodium azodisalicylate in ulcerative colitis.
ανά: Jewell, D, κ.ά.
Έκδοση: (1981)

THE DISPOSITION AND METABOLISM OF SULPHASALAZINE (SALICYLAZOSULFAPYRIDINE) IN MAN
ανά: Khan, A, κ.ά.
Έκδοση: (1982)

The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers.
ανά: Moraes, M, κ.ά.
Έκδοση: (1991)

Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases
ανά: Irene Mignini, κ.ά.
Έκδοση: (2023-12-01)

Therapeutic efficacy of jeoryeong-tang in dextran sulfate sodium-induced mouse model of inflammatory bowel disease
ανά: Il-Woong Jang, κ.ά.
Έκδοση: (2025-01-01)

Therapeutic targets in inflammatory bowel disease
ανά: Daniela Fluxa, κ.ά.
Έκδοση: (2019-07-01)

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents
ανά: Orazio Palmieri, κ.ά.
Έκδοση: (2024-06-01)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
ανά: Chang Soo Eun
Έκδοση: (2017-01-01)

Using systems medicine to identify a therapeutic agent with potential for repurposing in inflammatory bowel disease
ανά: Katie Lloyd, κ.ά.
Έκδοση: (2020-11-01)

Bicervical Normal Uterus with Normal Vagina and Anteroposterior Disposition of the Double Cervix
ανά: José Morales-Roselló, κ.ά.
Έκδοση: (2011-01-01)

The discovery of the foxglove as a therapeutic agent
ανά: Aronson, J
Έκδοση: (1987)

Therapeutic Drug Monitoring in Inflammatory Bowel Disease
ανά: Manoel Alvaro de Freitas Lins Neto, κ.ά.
Έκδοση: (2023-12-01)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
ανά: Marafini I, κ.ά.
Έκδοση: (2020-06-01)

Evolving Therapeutic Strategies in the Inflammatory Bowel Disease
ανά: Soo-Young Na, κ.ά.
Έκδοση: (2018-02-01)

Sodium phosphate solution as bowel preparation for outpatient diagnostic and therapeutic manipulations
ανά: N. V. Topchy, κ.ά.
Έκδοση: (2017-12-01)

Advances in biological agents in the treatment of inflammatory bowel disease
ανά: Na LI, κ.ά.
Έκδοση: (2022-08-01)

The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
ανά: Tri Hapsoro Guno, κ.ά.
Έκδοση: (2017-12-01)

Neurochemical studies in normal volunteers
ανά: Nutt, D, κ.ά.
Έκδοση: (1988)

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
ανά: Bufu Tang, κ.ά.
Έκδοση: (2020-11-01)

Translating immunology into therapeutic concepts for inflammatory bowel disease
ανά: Uhlig, HH, κ.ά.
Έκδοση: (2018)

Genetically engineered bacteria as inflammatory bowel disease therapeutics
ανά: Zhen-Ping Zou, κ.ά.
Έκδοση: (2024-12-01)

Ferroptosis: A therapeutic opportunity of inflammatory bowel disease
ανά: Yulin Ye, κ.ά.
Έκδοση: (2024-04-01)

Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease
ανά: Sung Noh Hong
Έκδοση: (2017-09-01)

Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease
ανά: Qiuyun Xu, κ.ά.
Έκδοση: (2021-03-01)

Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
ανά: Giovanni Pallio
Έκδοση: (2023-09-01)

Gut microbiome–based therapeutics in inflammatory bowel disease
ανά: Kelly A. Hu, κ.ά.
Έκδοση: (2023-04-01)

Nutritional approach as therapeutic manipulation in inflammatory bowel disease
ανά: Jin Young Yoon
Έκδοση: (2019-10-01)

The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
ανά: Tao Zuo, κ.ά.
Έκδοση: (2018-09-01)

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases
ανά: Broering MF, κ.ά.
Έκδοση: (2024-04-01)

THE DISPOSITION OF ORAL RUBIDIUM CHLORIDE IN ESSENTIAL-HYPERTENSION
ανά: Boon, N, κ.ά.
Έκδοση: (1982)

The dispositional effects of holidays on investor sentiment: Therapeutic and hygienic
ανά: Qing Liu, κ.ά.
Έκδοση: (2023-04-01)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
ανά: Abdullahi, ST, κ.ά.
Έκδοση: (2019)

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
ανά: Jürgen B. Bulitta, κ.ά.
Έκδοση: (2019-07-01)

Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease.
ανά: Mahida, Y, κ.ά.
Έκδοση: (1989)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
ανά: Al Sulais E, κ.ά.
Έκδοση: (2020-01-01)

THE EFFECT OF DIGOXIN ON THE INVIVO DISPOSITION OF AN ORAL LOAD OF RUBIDIUM CHLORIDE
ανά: Aronson, J, κ.ά.
Έκδοση: (1982)

Agentes biológicos en enfermedad inflamatoria intestinal Biological agents in inflammatory bowel disease
ανά: M. Van Domselaar
Έκδοση: (2008-12-01)

Telocytes in inflammatory bowel diseases: contributions to pathology and therapeutic potentials
ανά: Ronaldo Paolo Panganiban, κ.ά.
Έκδοση: (2025-01-01)

Inflammatory Bowel Disease Therapeutics: A Focus on Probiotic Engineering
ανά: Jayshree Mishra, κ.ά.
Έκδοση: (2022-01-01)